JP2022532996A5 - - Google Patents
Info
- Publication number
- JP2022532996A5 JP2022532996A5 JP2021563352A JP2021563352A JP2022532996A5 JP 2022532996 A5 JP2022532996 A5 JP 2022532996A5 JP 2021563352 A JP2021563352 A JP 2021563352A JP 2021563352 A JP2021563352 A JP 2021563352A JP 2022532996 A5 JP2022532996 A5 JP 2022532996A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025063227A JP2025109712A (ja) | 2019-04-26 | 2025-04-07 | リツキシマブ耐性キメラ抗原受容体およびその用途 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962839455P | 2019-04-26 | 2019-04-26 | |
| US62/839,455 | 2019-04-26 | ||
| US202063005041P | 2020-04-03 | 2020-04-03 | |
| US63/005,041 | 2020-04-03 | ||
| PCT/US2020/029775 WO2020219848A1 (en) | 2019-04-26 | 2020-04-24 | Rituximab-resistant chimeric antigen receptors and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025063227A Division JP2025109712A (ja) | 2019-04-26 | 2025-04-07 | リツキシマブ耐性キメラ抗原受容体およびその用途 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022532996A JP2022532996A (ja) | 2022-07-21 |
| JP2022532996A5 true JP2022532996A5 (https=) | 2023-04-28 |
| JPWO2020219848A5 JPWO2020219848A5 (https=) | 2023-04-28 |
| JP7664180B2 JP7664180B2 (ja) | 2025-04-17 |
Family
ID=70847489
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021563352A Active JP7664180B2 (ja) | 2019-04-26 | 2020-04-24 | リツキシマブ耐性キメラ抗原受容体およびその用途 |
| JP2025063227A Pending JP2025109712A (ja) | 2019-04-26 | 2025-04-07 | リツキシマブ耐性キメラ抗原受容体およびその用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025063227A Pending JP2025109712A (ja) | 2019-04-26 | 2025-04-07 | リツキシマブ耐性キメラ抗原受容体およびその用途 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11896617B2 (https=) |
| EP (2) | EP4295851A3 (https=) |
| JP (2) | JP7664180B2 (https=) |
| KR (1) | KR20220004076A (https=) |
| CN (1) | CN113728001B (https=) |
| AU (2) | AU2020263495B2 (https=) |
| BR (1) | BR112021021178A2 (https=) |
| CA (1) | CA3134308A1 (https=) |
| CO (1) | CO2021014121A2 (https=) |
| DK (1) | DK3959235T5 (https=) |
| ES (1) | ES2961314T3 (https=) |
| FI (1) | FI3959235T3 (https=) |
| IL (1) | IL287487A (https=) |
| MX (1) | MX2021012820A (https=) |
| MY (1) | MY204280A (https=) |
| PE (1) | PE20212369A1 (https=) |
| PH (1) | PH12021552415A1 (https=) |
| SA (1) | SA521430654B1 (https=) |
| SG (1) | SG11202111031RA (https=) |
| TW (1) | TWI865517B (https=) |
| WO (1) | WO2020219848A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20211266A1 (es) * | 2017-10-31 | 2021-07-19 | Allogene Therapeutics Inc | Metodos y composiciones para la dosificacion de celulas t con receptor de antigeno quimerico alogenicas |
| JP2023545071A (ja) * | 2020-10-09 | 2023-10-26 | シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） | Ｐｄ１キメラポリペプチドを含む方法および組成物 |
| EP4271817A2 (en) | 2020-12-30 | 2023-11-08 | Alaunos Therapeutics, Inc. | Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof |
| AU2023362748A1 (en) * | 2022-10-20 | 2025-06-05 | Microcrispr Pvt Ltd. | Attenuation of cytokine release syndrome in immunotherapy |
| JP2025535441A (ja) * | 2022-10-20 | 2025-10-24 | マイクロ クリスパー プライベート リミテッド | 免疫療法におけるサイトカイン放出症候群の軽減 |
| AU2023362746A1 (en) * | 2022-10-20 | 2025-06-05 | Microcrispr Pvt Ltd. | Attenuation of cytokine release syndrome in immunotherapy |
| AU2023362749A1 (en) * | 2022-10-20 | 2025-06-05 | Microcrispr Pvt Ltd. | Attenuation of cytokine release syndrome in immunotherapy |
| JP2025535444A (ja) * | 2022-10-20 | 2025-10-24 | マイクロ クリスパー プライベート リミテッド | 免疫療法におけるサイトカイン放出症候群の軽減 |
| CN119700678A (zh) * | 2024-12-19 | 2025-03-28 | 武汉大学 | 一种司妥昔纳米球的合成及其偶联car-t细胞的方法 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
| US5869337A (en) | 1993-02-12 | 1999-02-09 | President And Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
| US5834266A (en) | 1993-02-12 | 1998-11-10 | President & Fellows Of Harvard College | Regulated apoptosis |
| US5830462A (en) | 1993-02-12 | 1998-11-03 | President & Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
| US20030036654A1 (en) | 1994-08-18 | 2003-02-20 | Holt Dennis A. | Synthetic multimerizing agents |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| CA2406864A1 (en) | 2000-02-24 | 2001-08-30 | Life Technologies Corporation | Simultaneous stimulation and concentration of cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| EP1438075A4 (en) | 2001-10-02 | 2006-04-19 | Inst Clayton De La Rech | METHOD AND COMPOSITIONS ASSOCIATED WITH LENTIVIRAL VECTORS WITH LIMITED EXPRESSION AND ITS APPLICATIONS |
| US20100196336A1 (en) | 2006-05-23 | 2010-08-05 | Dongsu Park | Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods |
| WO2011146862A1 (en) | 2010-05-21 | 2011-11-24 | Bellicum Pharmaceuticals, Inc. | Methods for inducing selective apoptosis |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| AU2012209103B2 (en) | 2011-01-26 | 2015-12-03 | Takeda Pharmaceutical Company Limited | Methods and compositions for the synthesis of multimerizing agents |
| CN110200997A (zh) | 2011-03-23 | 2019-09-06 | 弗雷德哈钦森癌症研究中心 | 用于细胞免疫治疗的方法和组合物 |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| KR102437522B1 (ko) * | 2012-05-25 | 2022-08-26 | 셀렉티스 | 면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법 |
| EP4303232A3 (en) | 2013-02-15 | 2024-04-17 | The Regents of The University of California | Chimeric antigen receptor and methods of use thereof |
| WO2014151960A2 (en) | 2013-03-14 | 2014-09-25 | Bellicum Pharmaceuticals, Inc. | Methods for controlling t cell proliferation |
| PL3546572T3 (pl) | 2013-05-13 | 2024-07-22 | Cellectis | Chimeryczny receptor antygenowy swoisty względem cd19 i jego zastosowania |
| WO2015017214A1 (en) | 2013-07-29 | 2015-02-05 | Bluebird Bio, Inc. | Multipartite signaling proteins and uses thereof |
| US10287354B2 (en) | 2013-12-20 | 2019-05-14 | Novartis Ag | Regulatable chimeric antigen receptor |
| JP2017505819A (ja) | 2014-02-04 | 2017-02-23 | カイト ファーマ インコーポレイテッドＫｉｔｅ Ｐｈａｒｍａ， Ｉｎｃ | Ｂ細胞悪性腫瘍及び他のがんの治療に有用な自己ｔ細胞を産生する方法、並びにその組成物 |
| US10934346B2 (en) | 2014-02-14 | 2021-03-02 | Bellicum Pharmaceuticals, Inc. | Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12 |
| GB201403972D0 (en) * | 2014-03-06 | 2014-04-23 | Ucl Business Plc | Chimeric antigen receptor |
| ES2791248T3 (es) * | 2014-08-19 | 2020-11-03 | Novartis Ag | Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer |
| US10888608B2 (en) * | 2014-09-02 | 2021-01-12 | Bellicum Pharmaceuticals, Inc. | Costimulation of chimeric antigen receptors by MyD88 and CD40 polypeptides |
| ES2869972T3 (es) | 2015-01-26 | 2021-10-26 | Cellectis | Sistemas de receptores de antígenos quiméricos dirigidos por mAb para clasificar/agotar células inmunitarias genomanipuladas |
| GB201518792D0 (en) * | 2015-10-23 | 2015-12-09 | Univ Manchester | Production of proteins |
| WO2017103613A1 (en) | 2015-12-18 | 2017-06-22 | Ucl Business Plc | Treatment |
| MX2018010924A (es) | 2016-03-11 | 2019-02-13 | Bluebird Bio Inc | Células efectoras inmunitarias con edición genómica. |
| EP3443001B1 (en) * | 2016-04-11 | 2025-04-30 | Obsidian Therapeutics, Inc. | REGULATED BIOCIRCUIT SYSTEMS |
| GB201609597D0 (en) | 2016-06-01 | 2016-07-13 | Univ Sheffield | Therapy |
| SG11201810640RA (en) * | 2016-06-08 | 2018-12-28 | Intrexon Corp | Cd33 specific chimeric antigen receptors |
| KR102746901B1 (ko) * | 2017-03-03 | 2024-12-26 | 옵시디안 테라퓨틱스, 인크. | Cd19 조성물 및 면역요법을 위한 방법 |
| EP4414380A3 (en) | 2017-03-31 | 2024-12-04 | Cellectis SA | Universal anti-cd22 chimeric antigen receptor engineered immune cells |
| EP3784785A4 (en) | 2018-04-23 | 2022-02-16 | Duke University | DOWNREGULATION OF SNCA EXPRESSION BY TARGETED EDITING OF DNA METHYLATION |
| CA3110922A1 (en) * | 2018-08-28 | 2020-03-05 | Immunotech Biopharm Co., Ltd. | Improved therapeutic t cell |
-
2020
- 2020-04-24 JP JP2021563352A patent/JP7664180B2/ja active Active
- 2020-04-24 CA CA3134308A patent/CA3134308A1/en active Pending
- 2020-04-24 ES ES20728258T patent/ES2961314T3/es active Active
- 2020-04-24 US US16/857,573 patent/US11896617B2/en active Active
- 2020-04-24 CN CN202080031593.1A patent/CN113728001B/zh active Active
- 2020-04-24 MY MYPI2021005771A patent/MY204280A/en unknown
- 2020-04-24 PH PH1/2021/552415A patent/PH12021552415A1/en unknown
- 2020-04-24 FI FIEP20728258.3T patent/FI3959235T3/fi active
- 2020-04-24 DK DK20728258.3T patent/DK3959235T5/da active
- 2020-04-24 AU AU2020263495A patent/AU2020263495B2/en active Active
- 2020-04-24 PE PE2021001764A patent/PE20212369A1/es unknown
- 2020-04-24 TW TW109113823A patent/TWI865517B/zh active
- 2020-04-24 WO PCT/US2020/029775 patent/WO2020219848A1/en not_active Ceased
- 2020-04-24 SG SG11202111031RA patent/SG11202111031RA/en unknown
- 2020-04-24 EP EP23186544.5A patent/EP4295851A3/en active Pending
- 2020-04-24 MX MX2021012820A patent/MX2021012820A/es unknown
- 2020-04-24 BR BR112021021178A patent/BR112021021178A2/pt unknown
- 2020-04-24 EP EP20728258.3A patent/EP3959235B1/en active Active
- 2020-04-24 KR KR1020217036085A patent/KR20220004076A/ko active Pending
-
2021
- 2021-10-21 IL IL287487A patent/IL287487A/en unknown
- 2021-10-21 SA SA521430654A patent/SA521430654B1/ar unknown
- 2021-10-22 CO CONC2021/0014121A patent/CO2021014121A2/es unknown
-
2023
- 2023-12-26 US US18/395,996 patent/US12447178B2/en active Active
-
2025
- 2025-04-07 JP JP2025063227A patent/JP2025109712A/ja active Pending
- 2025-12-11 AU AU2025279733A patent/AU2025279733A1/en active Pending